Produção Nacional
Revisado por pares
Protective efficacy of different strategies employing Mycobacterium leprae heat-shock protein 65 against tuberculosis
2008; Taylor & Francis; Volume: 8; Issue: 9 Linguagem: Inglês
10.1517/14712598.8.9.1255
ISSN1744-7682
AutoresPatricia Souza, Carlos R. Zárate-Bladés, Juliana I. Hori, Simone G. Ramos, Deison Soares de Lima, Tatiana Schneider, Rogério Silva Rosada, Lucimara Gaziola de la Torre, Maria Helena Andrade Santana, Izaíra Tincani Brandão, Ana Paula Masson, Arlete Aparecida Martins Coelho‐Castelo, Vânia Luiza Deperon Bonato, Fábio C. S. Galetti, Eduardo Dantas Casillo Gonçalves, Domingos Alexandre Ciccone Botte, Jeanne BM Machado, Célio Lopes Silva,
Tópico(s)Escherichia coli research studies
ResumoBackground: Tuberculosis is a major threat to human health. The high disease burden remains unaffected and the appearance of extremely drug-resistant strains in different parts of the world argues in favor of the urgent need for a new effective vaccine. One of the promising candidates is heat-shock protein 65 when used as a genetic vaccine (DNAhsp65). Nonetheless, there are substantial data indicating that BCG, the only available anti-TB vaccine for clinical use, provides other important beneficial effects in immunized infants. Methods: We compared the protective efficacy of BCG and Hsp65 antigens in mice using different strategies: i) BCG, single dose subcutaneously; ii) naked DNAhsp65, four doses, intramuscularly; iii) liposomes containing DNAhsp65, single dose, intranasally; iv) microspheres containing DNAhsp65 or rHsp65, single dose, intramuscularly; and v) prime–boost with subcutaneous BCG and intramuscular DNAhsp65. Results: All the immunization protocols were able to protect mice against infection, with special benefits provided by DNAhsp65 in liposomes and prime–boost strategies. Conclusion: Among the immunization protocols tested, liposomes containing DNAhsp65 represent the most promising strategy for the development of a new anti-TB vaccine.
Referência(s)